RAY1225
Sources
registry, as of 2025-07-17Stale
https://clinicaltrials.gov/study/NCT06893016
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 640. Conditions Obesity. The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
ClinicalTrials.gov NCT06893016 protocol and results modules
registry, as of 2025-03-19Stale
https://clinicaltrials.gov/study/NCT06254261
A Study of RAY1225 in Participants With Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 270. Conditions Obesity. The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
ClinicalTrials.gov NCT06254261 protocol and results modules
registry, as of 2026-03-05Stale
https://clinicaltrials.gov/study/NCT05835752
The Safety, Tolerability and Pharmacokinetic Study of RAY1225. Overall status COMPLETED. Phases PHASE1. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 68. Conditions Obese; Healthy. This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
ClinicalTrials.gov NCT05835752 protocol and results modules
registry, as of 2026-01-23Stale
https://clinicaltrials.gov/study/NCT07362030
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 32. Conditions Obesity. The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and
ClinicalTrials.gov NCT07362030 protocol and results modules